Actively Recruiting
Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
Led by Centre Oscar Lambret · Updated on 2026-03-18
75
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
Sponsors
C
Centre Oscar Lambret
Lead Sponsor
M
MATMATECH
Collaborating Sponsor
AI-Summary
What this Trial Is About
This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer. Patients will be randomly assigned to one of two parallel treatment groups until the six-month assessment: The first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators. The second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.
CONDITIONS
Official Title
Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
INCLUSION CRITERIA :
- Patient over 40 years
- Presenting disabling vaginal dryness symptoms despite well-administered local moisturizing treatment, attested by a vaginal dryness score ≥3
- Patient undergoing adjuvant treatment for breast cancer
- Patient treated with aromatase inhibitors +/- LHRH agonist for at least 3 months with a planned remaining duration of at least 12 months
- Patient affiliated to a social security organization
- Patient having signed the informed consent for the present study
EXCLUSION CRITERIA:
-
Contraindications related to the radiofrequency technique:
- Ongoing urinary tract infection
- Pacemaker
- IUD intrauterine device
- Pregnancy
-
Mucocutaneous disease with vulvovaginal localization: infection, sore, scleratrophic lichen, psoriasis, eczema, etc.
-
Neurodegenerative disease with perineal involvement
-
Current or recent treatment (within the last 12 months) with other physical methods: vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection or lipo-modeling.
-
Pregnant or breast-feeding women
-
Patients under guardianship or trusteeship.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Oscar Lambret
Lille, France, 59020
Actively Recruiting
Research Team
F
Fanny BEN OUNE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here